Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

RA-P-OCD-01 Recruiting

2024-518391-31-00 Psychosis and or Obsessive Compulsive Disorder, with an 2024-11-05
A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie… Recruiting

2023-505242-25-00 High-Risk Monoclonal Gammopathy of Undetermined Signifi 2024-11-05
An Off-Label Single Arm Clinical Study to Evaluate the Efficacy and Safety of doxecitine and doxribtimine in Adult Subjects with Thymidine K… Recruiting

2024-510763-35-00 Organic compound 2024-11-05
Ruxolitinib rollover study Recruiting

2023-507225-42-00 Myelofibrosis 2024-11-05
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 2024-11-04
Use of Levosimendan as treatment of aneurysmal Hemorrhage Recruiting

2024-514242-36-00 subarachnoid hemorrhages of aneurysmal origin (HSAa) 2024-11-04
Dosimetry based PRRT versus standard dose PRRT with Lu-177-DOTATOC in NEN patients- a randomized study; a step towards tailored PRRT. Recruiting

2024-517240-62-00 Neuroendocrine Tumor 2024-11-04
Neoadjuvant and postoperative treatment with dabrafenib and trametinib for papillary craniopharyngioma Recruiting

2024-517611-67-00 papillary craniopharyngioma 2024-11-01
MANUS trial Recruiting

2024-515387-31-00 Systemic Sclerosis 2024-11-01
A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen i… Recruiting

2024-514899-41-00 Breast cancer 2024-10-31
No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting

2024-515470-26-00 Relapsing Remitting Multiple Sclerosis 2024-10-31
Phase II Study of Avelumab plus chemotherapy for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC). Mo… Recruiting

2024-516777-77-00 Resectable Gastric cancer (GC) or Gastroesophageal Junc 2024-10-31
Novel treatment with botulinum toxin for erectile dysfunction unresponsive to conventional treatment Recruiting

2024-514518-10-00 Erectile dysfunction 2024-10-31
Preoperative amivantamab or amivantamab and carboplatin/pemetrexed treatment in patients with resectable non-small-cell lung cancer harborin… Recruiting

2023-505662-28-00 Non-small-cell lung cancer stages I B, II and selected 2024-10-30
Small patient study to explore the anticancer effect of cannabis oil in untreatable patients with liver cancer Recruiting

2024-514049-13-02 Patients with untreatable hepatocellulare carcinoma 2024-10-29
LENVABLA Lenvatinib in neo-adjuvant and adjuvant therapy for poor-prognosis BCLC A HepatoCellular Carcinoma treated by percutaneous ablatio… Recruiting

2024-514606-31-00 Patients with Biopsy-proven or radiologically-suggested 2024-10-29
BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms Recruiting

2024-514783-78-00 psychological disorders: PTSD; Anxiety disorders 2024-10-29
CHASIT Recruiting

2024-516940-24-00 locally advanced urothelial cancer. 2024-10-29
DAROTAXEL Recruiting

2024-516939-28-00 metastatic castration-resistant prostate cancer 2024-10-28
Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic … Recruiting

2024-517214-16-00 Alzheimer’s disease 2024-10-28
Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial Recruiting

2024-517230-17-00 Intracerebral haemorrhage 2024-10-28
Preventing liver recurrence after partial hepatectomy for intrahepatic cholangiocarcinoma using adjuvant hepatic arterial infusion pump chem… Recruiting

2024-513726-33-00 Intrahepatic cholangiocarcinoma (iCCA) 2024-10-25
not applicable Recruiting

2023-508953-16-00 Newly diagnosed high grade glioma (HGG) including diffu 2024-10-25
Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide Recruiting

2024-511026-31-01 Glioblastoma grade 4 2024-10-24